General Information of the Compound
| Compound ID |
CP0062070
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
Show/Hide
|
||||||||||||||||||
| Synonyms |
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
745-65-3
Alprostadil
Alprostadil (JP15/USP/INN)
Alprostadil(Caverject)
Alprostadilum
BML1-F06
Befar
Befar (TN)
CHEMBL495
Caverject
Caverject (TN)
Edex
Edex (TN)
FemLife
Femprox
HEI-507
Lipo-alprostadil
Lipoprost
Liprostin
MR 256
MR-256
Minprog
Muse
Muse (TN)
PGE-1
PGE1
PGE1 Oligomer
Prink (TN)
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
Prostaglandin E1
Prostandin
Prostavasin
Prostin VR
Prostin VR pediatric (TN)
Prostivas
RayVa
Sugiran
U-10136
UNII-F5TD010360
Vasaprostan
Viridal
Vitaros
alprostadil
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C20H34O5
|
||||||||||||||||||
| Molecular Weight |
354.487
|
||||||||||||||||||
| Canonical SMILES |
CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
||||||||||||||||||
| CAS |
745-65-3
119314-69-1
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT03222, ATP-binding cassette sub-family C member 3
Protein ID: PT05334, ATP-binding cassette sub-family C member 4
Protein ID: PT02279, Prostacyclin receptor
Protein ID: PT02988, Prostaglandin E2 receptor EP1 subtype
Protein ID: PT02989, Prostaglandin E2 receptor EP2 subtype
Protein ID: PT02345, Prostaglandin E2 receptor EP3 subtype
Protein ID: PT02346, Prostaglandin E2 receptor EP4 subtype
Protein ID: PT06205, Solute carrier organic anion transporter family member 2A1
Clinical Information about the Compound